Merck funds protein-degrading technology; Shire expects approval for a new ADHD medication in 2017; state biosimilar notification laws focus on subtext
Five things for pharma marketers to know: Thursday, March 19
A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer’s research
AstraZeneca, Joslin Diabetes Center ink three-year collaboration
March 11, 2015
4:30 pm
The partners will focus on developing treatments for metabolic disorders.
Sanofi lays off 100 at Boston R&D hub
February 11, 2015
5:00 pm
The Paris-based drugmaker has axed 100 oncology and global R&D employees as part of a reorganization effort.
J&J inks Alzheimer’s vaccine deal
January 12, 2015
4:49 pm
The $509-million agreement gives J&J rights to AC Immune’s experimental anti-Tau vaccine.
J&J subsidiary inks $35M RNA deal
January 5, 2015
5:16 pm
The ISIS Pharmaceuticals collaboration will focus on gastrointestinal autoimmune disorders.
Daiichi increases efforts to break into opioid market
The drugmaker is collaborating with Charleston Laboratories in the development and commercialization of hydrocodone products. The deal means Daiichi Sankyo now has two pipeline opiates.
BMS enters two immuno-oncology deals
May 27, 2014
5:43 pm
The drugmaker has paired up with Incyte and CytomyX in two separate deals.